Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Feb 10, 2017 (10 years ago)

Pioglitazone and Glimepiride Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Dissolution Specifications

Cause type: Dissolution failure

The tablet or capsule did not dissolve within specification. Dissolution controls how much drug the body absorbs; a failure can change the effective dose. All dissolution failure recalls.

What was recalled

Pioglitazone and Glimepiride Tablets, USP, 30 mg/4 mg, 30 count bottles, Rx only, Manufactured by Lek Pharmaceuticals d.d., Verovskova Ulica 57, Ljubljana, - SI-1526, Slovenia --- NDC 0781-5635-31

Affected NDC 0781-5635-31

Compare with the code on your package — it is the most precise check available.

Drug: Glimepiride Category: Diabetes Medication

Recalling firm
Sandoz Inc
NDC code
0781-5635-31
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0515-2017 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Glimepiride recalls

See all
Class III · Low risk

Glimepiride Tablets

Misprint on tablet

Ongoing Other Dr. Reddy's Laboratories, Inc. D-0313-2024
Class III · Low risk

Glimepiride Tablets

Misprint on tablet

Ongoing Other Dr. Reddy's Laboratories, Inc. D-0312-2024
Class II · Moderate risk

Glimepiride USP

CGMP deviations.

Terminated cGMP deviation PD-Rx Pharmaceuticals, Inc. NDC 43063-0587-90 D-0559-2023
Class II · Moderate risk

Glimepiride Tablets USP

cGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.

Ongoing cGMP deviation Preferred Pharmaceuticals, Inc. NDC 68788-8066-9 D-0527-2023
Class II · Moderate risk

Glimepiride Tablets

cGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.

Ongoing cGMP deviation Preferred Pharmaceuticals, Inc. NDC 68788-8095-9 D-0517-2023

Other recalls by Sandoz Inc

All 2017 recalls
Class III · Low risk

Focalin XR

Labeling: Incorrect or Missing Lot and/or Exp Date

Ongoing Labeling / mix-up Sandoz Inc D-0608-2026